ArticleSurgical case reports2026
Pathologic Complete Response to Modified FOLFIRINOX Enabling Conversion Surgery in Pancreatic Acinar Cell Carcinoma on Hemodialysis: A Case Report.
Article in Surgical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWith recent advances in systemic chemotherapy for pancreatic cancer, a subset of patients with initially unresectable disease, particularly those who respond favorably to treatment, can now undergo conversion surgery (CS) and achieve prolonged survival. However, in patients undergoing hemodialysis (HD), optimal chemotherapy dosing and dialysis scheduling have not been established, raising concerns about increased chemotherapy-related toxicity and uncertain antitumor efficacy. Here, we report a case in which chemotherapy was successfully administered to a HD patient with unresectable locally advanced pancreatic cancer. CASE PRESENTATION: A 48-year-old male on maintenance HD was diagnosed with pancreatic head cancer, pathologically confirmed as acinar cell carcinoma (ACC). The tumor showed a 270° involvement of the superior mesenteric vein and a 200° contact with the superior mesenteric artery. The patient received 19 cycles of modified FOLFIRINOX (mFFX) with a uniform 40% dose reduction under an adjusted dialysis schedule. The primary tumor decreased in size, achieving a partial response according to Response Evaluation Criteria In Solid Tumors (RECIST). Subsequently, the patient underwent pancreaticoduodenectomy with portal vein resection. Pathological examination revealed a pathological complete response. No adjuvant chemotherapy was administered, and no recurrence has been observed during 3 years of postoperative follow-up.
conclusionsWe successfully administered prolonged mFFX in a dialysis patient with unresectable pancreatic head ACC, enabling CS with curative intent. This case suggests that carefully dose-adjusted mFFX with appropriate dialysis scheduling can be a feasible and effective treatment option for selected HD patients with unresectable pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.